30,405 Shares in Tocagen Inc (TOCA) Acquired by Goldman Sachs Group Inc.
Goldman Sachs Group Inc. purchased a new stake in shares of Tocagen Inc (NASDAQ:TOCA) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 30,405 shares of the company’s stock, valued at approximately $366,000. Goldman Sachs Group Inc. owned about 0.19% of Tocagen at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. New York State Common Retirement Fund bought a new position in Tocagen during the 2nd quarter valued at about $108,000. TD Asset Management Inc. bought a new position in Tocagen during the 2nd quarter valued at about $158,000. Schwab Charles Investment Management Inc. bought a new position in Tocagen during the 2nd quarter valued at about $165,000. Teachers Advisors LLC bought a new position in Tocagen during the 2nd quarter valued at about $181,000. Finally, Wells Fargo & Company MN bought a new position in Tocagen during the 2nd quarter valued at about $183,000. Institutional investors own 37.88% of the company’s stock.
Several research firms have issued reports on TOCA. Stifel Nicolaus reissued a “buy” rating and issued a $24.00 price objective on shares of Tocagen in a research report on Tuesday, July 25th. Zacks Investment Research raised shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st.
Shares of Tocagen Inc (NASDAQ:TOCA) opened at $9.96 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03. Tocagen Inc has a 52-week low of $8.60 and a 52-week high of $17.95.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. research analysts forecast that Tocagen Inc will post -2.88 EPS for the current fiscal year.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Stock Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related stocks with our FREE daily email newsletter.